Issac Jacob

Director, Europe
Healthcare

Issac joined Results as a Director in late 2019. He has spent over 15 years in investment banking and corporate advisory in New York and London focused primarily on the healthcare and TMT sectors. He also has experience executing cross-border transactions in emerging markets.

He has worked with private equity and corporate clients on a variety of transactions and projects involving M&A, debt, equity, licensing, valuations and fundraising. In Europe, he was with the healthcare investment banking team at Bank of America, M&A team at Standard Chartered Bank, and most recently with PharmaVentures, a specialist healthcare corporate advisory firm. Prior to being in Europe, he was based in New York with JP Morgan’s M&A Telecom, Media and Technology team, and in the Healthcare and Technology teams at Salomon Smith Barney (Citigroup).

Issac received a BA in Economics from Columbia College, a Master’s in International Affairs from Columbia University and an MBA from Columbia Business School.

In his spare time, Issac is passionate about international affairs and history, enjoys spending time with his family, and likes sports.

You miss 100% of the shots you don’t take. —Wayne Gretzky

Latest Insights

Insights
9th July 2020

Deal activity and valuations in the healthcare sector during COVID-19

There has been a measurable impact on healthcare deal activity and valuations as a result of COVID-19. Major equity indices experienced a remarkable dip following the COVID-19 outbreak but appear to have stabilised and recovered the lost ground. Debt market spreads, especially sub-investment grade, spiked in March but have been gradually reducing as lockdown is […]

Reports
27th May 2020

Generic Pharmaceutical Market: M&A Activity

The global generic pharmaceutical market has experienced robust deal activity over the last 18 months to the end of 2019 but is now contending with the COVID-19 crisis which has had an immediate and unprecedented impact on health systems. It is yet unclear what the long-term general impact on generic drug usage will be, but […]